Currently out of the existing stock ratings of Uy Ear, 29 are a HOLD (23.97%), 92 are a BUY (76.03%).

Uy Ear

Work Performance Price Targets & Ratings Chart

Analyst Uy Ear, currently employed at MIZUHO, carries an average stock price target met ratio of 28.29% that have a potential upside of 28.31% achieved within 120 days.

Uy Ear’s has documented 214 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALKS, Alkermes Plc at 02-Jul-2026.

Wall Street Analyst Uy Ear

Analyst best performing recommendations are on QURE (UNIQURE NV).
The best stock recommendation documented was for QURE (UNIQURE NV) at 3/3/2026. The price target of $12 was fulfilled within 3 days with a profit of $2.97 (32.89%) receiving and performance score of 109.63.

Average potential price target upside

of $48.43 (54.16%) on SRPT (SAREPTA THERAPEUTICS).
of $12.92 (9.71%) on NBIX (NEUROCRINE BIOSCIENCES).
of $10.35 (35.38%) on ALKS (ALKERMES PLC).

ARQT Arcutis Biotherapeutics AVRO AVROBIO NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc EOLS Evolus OCGN Ocugen SELB Selecta Biosciences SRPT Sarepta Therapeutics RVNC Revance The QURE Uniqure NV SAGE Sage Therapeutic RLMD Relmada Therapeutics INAB In8bio RNAC Cartesian Therapeutics TECX Tectonic Therapeutic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Serge Belanger (NEEDHAM)